Interstitial Cystitis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Interstitial Cystitis - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Interstitial Cystitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Interstitial Cystitis: Overview
Interstitial cystitis (IC), also called bladder pain syndrome, is a chronic, or long-lasting, condition that causes painful urinary symptoms. Symptoms of IC may be different from person to person. For example, some people feel mild discomfort, pressure, or tenderness in the pelvic area. Other people may have intense pain in the bladder or struggle with urinary urgency, the sudden need to urinate, or frequency, the need to urinate more often. IC can occur at any age, including during childhood, but is most common in adult women and men. About twice as many women are affected as men.1 However, more men may struggle with IC than researchers originally thought. Some research suggests that women are more likely to develop IC if they have a history of being sexually abused or physically traumatized
'Interstitial Cystitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Interstitial Cystitis pipeline landscape is provided which includes the disease overview and Interstitial Cystitis treatment guidelines. The assessment part of the report embraces, in depth Interstitial Cystitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interstitial Cystitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Interstitial Cystitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interstitial Cystitis Emerging Drugs
Further product details are provided in the report……..
Interstitial Cystitis: Therapeutic Assessment
This segment of the report provides insights about the different Interstitial Cystitis drugs segregated based on following parameters that define the scope of the report, such as:
Interstitial Cystitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interstitial Cystitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interstitial Cystitis drugs.
Interstitial Cystitis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Interstitial Cystitis - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Interstitial Cystitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Interstitial Cystitis: Overview
Interstitial cystitis (IC), also called bladder pain syndrome, is a chronic, or long-lasting, condition that causes painful urinary symptoms. Symptoms of IC may be different from person to person. For example, some people feel mild discomfort, pressure, or tenderness in the pelvic area. Other people may have intense pain in the bladder or struggle with urinary urgency, the sudden need to urinate, or frequency, the need to urinate more often. IC can occur at any age, including during childhood, but is most common in adult women and men. About twice as many women are affected as men.1 However, more men may struggle with IC than researchers originally thought. Some research suggests that women are more likely to develop IC if they have a history of being sexually abused or physically traumatized
'Interstitial Cystitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Interstitial Cystitis pipeline landscape is provided which includes the disease overview and Interstitial Cystitis treatment guidelines. The assessment part of the report embraces, in depth Interstitial Cystitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interstitial Cystitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Interstitial Cystitis R&D. The therapies under development are focused on novel approaches to treat/improve Interstitial Cystitis.
This segment of the Interstitial Cystitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interstitial Cystitis Emerging Drugs
- Certolizumab pegol: UCB
- SI-722: Seikagaku Corporation
Further product details are provided in the report……..
Interstitial Cystitis: Therapeutic Assessment
This segment of the report provides insights about the different Interstitial Cystitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Interstitial Cystitis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Interstitial Cystitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interstitial Cystitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interstitial Cystitis drugs.
Interstitial Cystitis Report Insights
- Interstitial Cystitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Interstitial Cystitis drugs?
- How many Interstitial Cystitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interstitial Cystitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interstitial Cystitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Interstitial Cystitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Merck & Co
- PureTech Health
- Teva Pharmaceutical Industries
- Integrative Therapeutics, Inc.
- Lipella Pharmaceuticals, Inc.
- Astellas Pharma
- Seikagaku Corporation
- UCB
- Alivio Therapeutics
- Urigen Pharmaceuticals
- PureTech Health
- Gefapixant
- LYT 503
- Fremanezumab
- Peppermint oil
- LP-08
- ASP6294
- SI-722
- Certolizumab
- ALV 107
- URG-101
- LYT 503
- Mirabegron
Introduction
Executive Summary
Interstitial Cystitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Certolizumab pegol: UCB
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Gefapixant: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
LYT 503: PureTech Health
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interstitial Cystitis Key Companies
Interstitial Cystitis Key Products
Interstitial Cystitis- Unmet Needs
Interstitial Cystitis- Market Drivers and Barriers
Interstitial Cystitis- Future Perspectives and Conclusion
Interstitial Cystitis Analyst Views
Interstitial Cystitis Key Companies
Appendix
Executive Summary
Interstitial Cystitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Certolizumab pegol: UCB
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Gefapixant: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
LYT 503: PureTech Health
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interstitial Cystitis Key Companies
Interstitial Cystitis Key Products
Interstitial Cystitis- Unmet Needs
Interstitial Cystitis- Market Drivers and Barriers
Interstitial Cystitis- Future Perspectives and Conclusion
Interstitial Cystitis Analyst Views
Interstitial Cystitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Interstitial Cystitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Interstitial Cystitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Interstitial Cystitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Interstitial Cystitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
